Related references
Note: Only part of the references are listed.Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification
Andrew M. Leader et al.
CANCER CELL (2021)
The Identification and Validation of Two Heterogenous Subtypes and a Risk Signature Based on Ferroptosis in Hepatocellular Carcinoma
Zaoqu Liu et al.
FRONTIERS IN ONCOLOGY (2021)
Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC
Joe Yeong et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Genomic Alteration Characterization in Colorectal Cancer Identifies a Prognostic and Metastasis Biomarker: FAM83A|IDO1
Zaoqu Liu et al.
FRONTIERS IN ONCOLOGY (2021)
Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma
Zaoqu Liu et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy
Xu Lei et al.
CANCER LETTERS (2020)
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
A. J. Schoenfeld et al.
ANNALS OF ONCOLOGY (2020)
Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer
Kyungsoo Kim et al.
GENOME MEDICINE (2020)
IRF4 instructs effector Treg differentiation and immune suppression in human cancer
Giorgia Alvisi et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Identification of 5-Gene Signature Improves Lung Adenocarcinoma Prognostic Stratification Based on Differential Expression Invasion Genes of Molecular Subtypes
Zhimin Zheng et al.
BIOMED RESEARCH INTERNATIONAL (2020)
Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
Robert J. Walsh et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer
Si-si Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
S. Trebeschi et al.
ANNALS OF ONCOLOGY (2019)
T cell and dendritic cell interactions in lymphoid organs: More than just being in the right place at the right time
Milas Ugur et al.
IMMUNOLOGICAL REVIEWS (2019)
Compartmentalization of dendritic cell and T-cell interactions in the lymph node: Anatomy of T-cell fate decisions
Beatriz Leon et al.
IMMUNOLOGICAL REVIEWS (2019)
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review
Kathryn C. Arbour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cancer and the Immune System: The History and Background of Immunotherapy
Maura Abbott et al.
SEMINARS IN ONCOLOGY NURSING (2019)
Evaluation of variable selection methods for random forests and omics data sets
Frauke Degenhardt et al.
BRIEFINGS IN BIOINFORMATICS (2019)
Lung cancer epigenetics: From knowledge to applications
Michael Duruisseaux et al.
SEMINARS IN CANCER BIOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
Pornpimol Charoentong et al.
CELL REPORTS (2017)
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
J. M. Pitt et al.
ANNALS OF ONCOLOGY (2016)
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
J. M. Kim et al.
ANNALS OF ONCOLOGY (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy A Report From the US Food and Drug Administration
Dickran Kazandjian et al.
JAMA ONCOLOGY (2016)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment
Thomas F. Gajewski
SEMINARS IN ONCOLOGY (2015)
High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4(+) T cells in human melanoma
Carsten Linnemann et al.
NATURE MEDICINE (2015)
Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells
Jeremy Goc et al.
CANCER RESEARCH (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
Thomas F. Gajewski et al.
CURRENT OPINION IN IMMUNOLOGY (2013)
Regulatory T cells: recommendations to simplify the nomenclature
Abul K. Abbas et al.
NATURE IMMUNOLOGY (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Measurement of mRNA abundance using RNA-seq data: RPKM measure is inconsistent among samples
Gunter P. Wagner et al.
THEORY IN BIOSCIENCES (2012)
What is principal component analysis?
Markus Ringner
NATURE BIOTECHNOLOGY (2008)
The tumour microenvironment as a target for chemoprevention
Adriana Albini et al.
NATURE REVIEWS CANCER (2007)